Related Experiment Videos
Comparative toxicities of third-generation cephalosporins
The American Journal of Medicine
|August 9, 1985
Summary
Ceftazidime showed a favorable safety profile compared to other third-generation cephalosporins. Adverse effects were comparable, with low rates of drug-related reactions and specific laboratory abnormalities.
Area of Science:
- Pharmacology
- Clinical Medicine
- Infectious Diseases
Background:
- Ceftazidime is a third-generation cephalosporin antibiotic.
- Comparative safety data with other cephalosporins are crucial for clinical decision-making.
Purpose of the Study:
- To compare the adverse effects of ceftazidime with other cephalosporins.
- To evaluate the safety profile of ceftazidime in a large patient cohort.
Main Methods:
- Retrospective analysis of adverse event data from 2,539 ceftazidime-treated patients.
- Comparison of ceftazidime's safety profile against cefoperazone, cefotaxime, ceftizoxime, and moxalactam.
Main Results:
- 6.2% of ceftazidime patients experienced possibly or probably drug-related adverse reactions.
- Ceftazidime demonstrated favorable renal, hepatic, hematopoietic, and hemostatic safety compared to other third-generation cephalosporins.
- Low incidences of specific adverse events were reported, including increased creatinine (0.8%), BUN (1.6%), hepatic abnormalities (~6%), diarrhea (1.3%), and pseudomembranous colitis (0.12%).
Conclusions:
- Ceftazidime exhibits a comparable safety profile to other third-generation cephalosporins.
- The incidence of colonization and superinfections with ceftazidime is similar to other agents in its class.